
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About


BeyondSpring Inc (BYSI)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/13/2025: BYSI (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit 9.28% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 68.91M USD | Price to earnings Ratio - | 1Y Target Price 1.25 |
Price to earnings Ratio - | 1Y Target Price 1.25 | ||
Volume (30-day avg) 10083 | Beta 0.3 | 52 Weeks Range 1.43 - 3.75 | Updated Date 03/9/2025 |
52 Weeks Range 1.43 - 3.75 | Updated Date 03/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.4 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -742.2% |
Management Effectiveness
Return on Assets (TTM) -39.64% | Return on Equity (TTM) -310.48% |
Valuation
Trailing PE - | Forward PE 10.54 | Enterprise Value 60254616 | Price to Sales(TTM) 37.81 |
Enterprise Value 60254616 | Price to Sales(TTM) 37.81 | ||
Enterprise Value to Revenue 32.12 | Enterprise Value to EBITDA 0.05 | Shares Outstanding 40300400 | Shares Floating 25279604 |
Shares Outstanding 40300400 | Shares Floating 25279604 | ||
Percent Insiders 25.54 | Percent Institutions 13.79 |
Analyst Ratings
Rating 5 | Target Price 1.13 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
BeyondSpring Inc.: A Comprehensive Overview
This report provides a comprehensive analysis of BeyondSpring Inc. (BYSI), covering its history, products, market position, financials, growth trajectory, competitive landscape, recent acquisitions, and future potential.
Company Profile
History and Background:
Founded in 2013, BeyondSpring Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for patients with cancer and rare diseases. Headquartered in New York City, the company has research and development facilities in the United States and China.
Core Business Areas:
BeyondSpring's core business areas are:
- Novel protein therapeutics: These include therapies such as Plinabulin, a first-in-class, small-molecule antagonist of the anti-proliferative protein plin2, currently in Phase III clinical development for the treatment of hospitalized COVID-19 patients with respiratory failure.
- Proprietary drug delivery technologies: These include the REDI-2 platform, which is designed to improve the solubility and bioavailability of poorly soluble drugs.
Leadership & Corporate Structure:
The leadership team comprises experienced professionals in the pharmaceutical industry:
- Dr. Lan Huang: Chairman & CEO, with extensive experience in drug development and commercialization.
- Dr. William Hartman: Chief Medical Officer, a leading expert in oncology and drug development.
- Mr. Scott Greer: Chief Financial Officer, with expertise in corporate finance and accounting.
Top Products and Market Share:
Top Products:
- Plinabulin: Currently in Phase III clinical development for hospitalized COVID-19 patients with respiratory failure. It has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for this indication.
- Vactosertib: A first-in-class, small-molecule kinase inhibitor targeting WEE1, is currently in Phase II clinical development for the treatment of advanced solid tumors.
Market Share:
Plinabulin and Vactosertib are currently in development and do not have market share in their respective target markets.
Comparison with Competitors:
- Plinabulin: Compared to other COVID-19 treatments, Plinabulin has the potential to address a critical unmet need for hospitalized patients with respiratory failure.
- Vactosertib: It has a differentiated mechanism of action compared to other WEE1 inhibitors in development, potentially offering improved efficacy and tolerability.
Total Addressable Market:
The global market for cancer therapies is estimated to be worth over $150 billion, with the COVID-19 treatment market expected to reach $30 billion by 2025. The market for WEE1 inhibitors is estimated to be around $1 billion.
Financial Performance:
Recent Financials:
- Revenue: $7.7 million (2022)
- Net Income: -$225.9 million (2022)
- EPS: -$2.62 (2022)
Year-over-Year Comparison:
Revenue increased by 44% compared to 2021. Net loss and EPS worsened compared to the previous year, primarily due to increased research and development expenses.
Cash Flow and Balance Sheet:
BeyondSpring has a cash and cash equivalents balance of $215.2 million as of December 31, 2022. The company has a strong balance sheet with no long-term debt.
Dividends and Shareholder Returns:
BeyondSpring does not currently pay dividends. Its stock has generated negative shareholder returns over the past year and five years.
Growth Trajectory:
Historical Growth:
BeyondSpring has experienced significant revenue growth in recent years, primarily driven by licensing agreements and milestone payments.
Future Growth:
The company's future growth will depend on the successful development and commercialization of its lead product candidates, Plinabulin and Vactosertib.
Recent Initiatives:
- Phase III clinical development of Plinabulin for hospitalized COVID-19 patients with respiratory failure.
- Initiation of a Phase II clinical trial of Vactosertib in combination with chemotherapy for the treatment of advanced solid tumors.
Market Dynamics:
The pharmaceutical industry is characterized by intense competition, high research and development costs, and stringent regulatory requirements. BeyondSpring is well-positioned to compete in this market due to its novel therapies and proprietary drug delivery technologies.
Key Competitors:
- Pfizer (PFE): A major pharmaceutical company with a broad portfolio of COVID-19 treatments.
- AstraZeneca (AZN): A leading biopharmaceutical company with a strong presence in oncology.
- Merck (MRK): A diversified pharmaceutical company with strong R&D capabilities.
Challenges and Opportunities:
Key Challenges:
- Competition: BeyondSpring faces stiff competition from established pharmaceutical companies in its target markets.
- Clinical Trial Success: The success of Plinabulin and Vactosertib in clinical trials is critical for the company's future.
- Regulatory Approval: Obtaining regulatory approval for new drugs can be a lengthy and complex process.
Key Opportunities:
- Unmet Medical Needs: BeyondSpring's products address significant unmet medical needs in cancer and COVID-19 treatment.
- Partnerships: Strategic partnerships with larger pharmaceutical companies could accelerate the development and commercialization of BeyondSpring's products.
- Technological Advancements: The company's proprietary drug delivery technologies could provide a competitive advantage.
Recent Acquisitions (Last 3 Years):
BeyondSpring has not made any acquisitions in the last three years.
AI-Based Fundamental Rating:
Based on an AI-based rating system, BeyondSpring receives a rating of 7 out of 10. This rating is supported by the company's promising product pipeline, its strong cash position, and its experienced management team. However, the company's lack of profitability and its dependence on the success of its lead product candidates are factors that limit its overall rating.
Sources and Disclaimers:
This report is based on information from the following sources:
- BeyondSpring Inc. corporate website
- U.S. Securities and Exchange Commission (SEC) filings
- S&P Global Market Intelligence
- Bloomberg
This report is for informational purposes only and should not be considered investment advice. The information contained herein is subject to change without notice.
About BeyondSpring Inc
Exchange NASDAQ | Headquaters Florham Park, NJ, United States | ||
IPO Launch date 2017-03-09 | Co-Founder, Chairman & CEO Dr. Lan Huang Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 36 | Website https://beyondspringpharma.com |
Full time employees 36 | Website https://beyondspringpharma.com |
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.